Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 30, 2023 16:15 ET | Source: Landos Biopharma, Inc.

Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D.

NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases,...
May 25, 2023 16:05 ET | Source: Landos Biopharma, Inc.

Landos Biopharma Announces 1-for-10 Reverse Stock Split

NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases,...
May 12, 2023 08:50 ET | Source: Landos Biopharma, Inc.

UPDATE -- Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results

NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, May ...
May 12, 2023 08:00 ET | Source: Landos Biopharma, Inc.

Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results

NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, May ...
March 23, 2023 08:00 ET | Source: Landos Biopharma, Inc.

Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results

On Track to Initiate Phase 2 Proof-of-Concept Trial in Ulcerative Colitis for NX-13 in the Second Quarter of 2023 and Report Topline Results by the Fourth Quarter of 2024 Projected Cash Runway into...
February 28, 2023 17:00 ET | Source: Landos Biopharma, Inc.

Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos’ Founder

Transaction Solidifies Company’s Near-Term Strategic Focus on Advancing Clinical Development of NX-13Company Remains On-Track to Initiate the NX-13 Phase 2 Proof-of-Concept Trial in Ulcerative Colitis...
January 11, 2023 07:00 ET | Source: Landos Biopharma, Inc.

Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn’s and Colitis Organization

NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for...
January 05, 2023 07:05 ET | Source: Landos Biopharma, Inc.

Landos Biopharma Provides Comprehensive Update on Clinical Development Plans

Advancing NX-13 Clinical Development for Treatment of Ulcerative Colitis On Track to Initiate Phase 2 Proof-of-Concept Trial for NX-13 in the Second Quarter of 2023 and Report Topline Data by the...
January 05, 2023 07:00 ET | Source: Landos Biopharma, Inc.

Landos Biopharma Announces $16.7 Million Private Placement Financing

NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for...
November 10, 2022 08:00 ET | Source: Landos Biopharma, Inc.

Landos Biopharma Reports Third Quarter 2022 Results and Provides Business Update

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases,...